30th July, 2026

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 **(BSE Scrip Code: 500420)**	The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 **(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

We would like to inform that the Board has at its meeting held today approved, inter alia, the Unaudited Standalone and Consolidated Financial Results along with limited review report of the Company for the quarter ended 30th June, 2026. The said financial results are enclosed herewith as an **Annexure A**.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter ended 30th June, 2026. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com

A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an **Annexure B**.

We would further like to inform that Ameera Shah (DIN: 00208095) will be completing her term as an Independent Director of the Company on 01st August, 2026.

The Board meeting commenced at 02:00 pm and concluded at 04:40 pm.

The above is for your information and record.

Email – investorservices@torrentpharma.com

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M TRIVEDI
Digitally signed by CHINTAN M TRIVEDI
Date: 2026.07.30 16:47:33 +05'30'

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Encl: A/a

Annexure A

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Torrent Pharmaceuticals Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended

To the Board of Directors of Torrent Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement") (in which are included the standalone financial information of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL), pursuant to the Scheme of Arrangement in the nature of Amalgamation of JBCPL with the Company which has been approved by the National Company Law Tribunal vide its order dated 06 July 2026 with the appointed date of 21 January 2026).

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to Note 4 to the accompanying standalone financial results, which describes the Scheme of Amalgamation (Scheme) of JBCPL with the Company, approved by the Honourable National Company Law Tribunal ("NCLT") vide its Order dated 6 July 2026 and a certified copy has been filed by the Company with the Registrar of Companies, Ahmedabad on 8 July 2026. In accordance with the scheme approved by NCLT, the amalgamation has been accounted for in the quarter ended 30 June 2026 with effect from the appointed date of 21 January 2026, and accordingly, the comparative financial information for the quarter and year ended 31 March 2026 has been restated.

   Our conclusion is not modified in respect of this matter.

6. The corresponding amounts for the quarter and year ended 31 March 2026, includes financial results of JBCPL (considered pursuant to the Scheme of Amalgamation of JBCPL with the Company as stated in Note 4), whose financial results reflect total assets of Rs. 4,823.50 crores as at 31 March 2026, total revenue of Rs. 712.74 crores, total net profit after tax Rs. 133.97 crores and total comprehensive income of Rs. 136.45 crores, for the period from 21 January 2026 to 31 March 2026. These financial results of JBCPL has been audited by other auditor who had expressed an unmodified opinion and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of JBCPL, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

7. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2026 as reported in these financial results are the balancing figures between audited figures in respect of full previous financial year as adjusted to give effect to the Scheme of Amalgamation of JBCPL with the Company which has been approved by the Honourable National Company Law Tribunal vide its order dated 6 July 2026 with the appointed date of 21 January 2026, and the audited year to date figures up to the third quarter of the previous financial year.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Sadashiv Shetty
Partner
Membership No.: 048648
UDIN:26048648MGVKOE5690

Ahmedabad
30 July 2026

TORRENT
PHARMA

TORRENT PHARMACEUTICALS LIMITED

Registered Office: "Avirat", Thaltej Shilaj Road, Ahmedabad – 380059, Gujarat, India, Ph.: + 91 79 26599000 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores)

Statement of Standalone Financial Results for the Quarter ended June 30, 2026

	Particulars	Quarter ended			Year ended
		30-Jun-2026 Unaudited	31-Mar-2026 Audited, Restated (Refer note 3 & 4)	30-Jun-2025 Audited	31-Mar-2026 Audited, Restated (Refer note 4)
1	**Revenue from operations**				
	(a) Revenue from contracts with customers	4073	3378	2567	11199
	(b) Other operating income	85	67	49	223
	Total revenue from operations	**4158**	**3445**	**2616**	**11422**
2	Other income (Refer Note 7)	(21)	(30)	(5)	(70)
3	**Total income (1 + 2)**	**4137**	**3415**	**2611**	**11352**
4	**Expenses**				
	(a) Cost of materials consumed	609	561	394	1748
	(b) Purchases of stock-in-trade	277	275	173	832
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	52	(44)	17	(47)
	(d) Employee benefits expense	677	598	453	1990
	(e) Finance costs	293	226	45	342
	(f) Depreciation and amortisation expense	575	490	187	1057
	(g) Other expenses	970	827	600	2620
	Total expenses	**3453**	**2933**	**1869**	**8542**
5	**Profit before exceptional items and tax (3 - 4)**	**684**	**482**	**742**	**2810**
6	Exceptional items (Refer Note 5)	21	66	-	89
7	**Profit before tax (5 - 6)**	**663**	**416**	**742**	**2721**
8	**Tax expense**				
	(a) Current tax	266	119	198	767
	(b) Deferred tax	(95)	(12)	(7)	(80)
	Total tax expense	**171**	**107**	**191**	**687**
9	**Net profit for the period (7 - 8)**	**492**	**309**	**551**	**2034**
10	**Other comprehensive income**				
	(A) (i) Items that will not be reclassified subsequently to profit or loss	(17)	18	(9)	(3)
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	4	(4)	2	1
	(B) (i) Items that will be reclassified subsequently to profit or loss	107	(97)	(27)	(191)
	(ii) Income tax relating to items that will be reclassified subsequently to profit or loss	(27)	25	7	48
	Total other comprehensive income	**67**	**(58)**	**(27)**	**(145)**
11	**Total comprehensive income (9 + 10)**	**559**	**251**	**524**	**1889**
12	Paid-up equity share capital (Face value of Rs. 5 each)	169.23	169.23	169.23	169.23
13	Other equity excluding revaluation reserves				17407
14	**Earnings per share (Face value of Rs. 5 each) (not annualised) :**				
	Basic (in Rs.)	12.94	7.74	16.28	58.70
	Diluted (in Rs.)	12.94	7.74	16.28	58.70

See accompanying notes to the standalone financial results

Notes:

1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on July 30, 2026. The statutory auditors have carried out limited review of the above said results. There is no qualification in the auditor's report on this statement of financial results.

2 The Company operates in a single segment i.e. Generic Formulation Business.

3 Figures for the quarter ended March 31, 2026 represents the difference between the audited figures in respect to the full financial year (as restated as per Note 4 below) and the published figures of nine months ended December 31, 2025, which were subjected to audit.

4 On January 21, 2026, the Company acquired controlling stake of 48.80% in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The Scheme of Amalgamation of JB Pharma with the Company was approved by the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, on July 6, 2026. Upon filing the Scheme with Registrars of Companies (ROC), the Scheme became effective on July 8, 2026, with an appointed date of January 21, 2026. Consequently, JB Pharma has been amalgamated with the Company and dissolved without being wound up.

On July 20, 2026, the Company allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JB Pharma as on the record date, July 17, 2026, in the share exchange ratio of 51 fully paid up equity shares having face value of Rs. 5 each of the Company for every 100 fully paid up equity shares having face value of Rs. 1 each of JB Pharma.

The management has determined the amalgamation to be a subsequent adjusting event and impact of amalgamation has been accounted using the pooling of interest method in accordance with Appendix C to Ind AS 103, Business Combinations, with effect from the appointed date, January 21, 2026, as specified in the approved Scheme. Accordingly, the comparative financial information for the year and quarter ended March 31, 2026, has been restated after recognizing the effect of amalgamation as above.

The amount of Revenue from operations and profit before tax published in the previous period before recognizing the effect of amalgamation are shown below -

(Rs. in crores)

Particulars	Quarter ended	Year ended
	31-Mar-2026	31-Mar-2026
Total revenue from operations	2735	10712
Profit Before Tax	592	2897

The financial results do not include the effect of the stamp duty payable in respect of the Scheme of Amalgamation, pending adjudication by the appropriate authority.

5 Exceptional items

(i)Includes Rs. 2 crores for the quarter ended June 30, 2026, Rs. 47 crores and Rs. 70 crores for quarter and year ended March 31, 2026 respectively, pertaining to regulatory and statutory fees, along with other related costs associated with JB Pharma's acquisition and merger as mentioned in Note 4 above.

(ii)Includes inventory write-off of Rs. 19 crores for the quarter ended June 30, 2026 consequent to fire incident at one of the erstwhile JB Pharma warehouses. No effect has been given to the related insurance claim, which is under assessment.

(iii)Includes severance compensation of Rs. 19 crores for the quarter and year ended March 31, 2026 , incurred on account of restructuring of JB Pharma's distribution network.

6 The listed non-convertible debentures of the company aggregating Rs. 10990 crores as at June 30, 2026 (as at March 31, 2026 : Rs.10990 Crores) are secured by first ranking exclusive charge by way of hypothecation over the designated account assets and the specified trademarks of the company including its future line extensions. The security cover thereof exceeds 110% of the principal amount and interest accrued on the said debentures.

The listed non-convertible debentures of the company aggregating Rs. 143 crores as at March 31, 2025 has been fully repaid during the year ended March 31, 2026.

7 Other income mainly includes interest income, dividend income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets.

8 Refer Annexure I for disclosure required pursuant to Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

For TORRENT PHARMACEUTICALS LIMITED

Place : Ahmedabad, Gujarat
Date : July 30, 2026

AMAN MEHTA
Managing Director
DIN : 08174906

ANNEXURE I : (Rs. in crores except as stated otherwise)

Additional Disclosure as per regulation 52(4) and 54(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	**Regulation No.**	**Quarter ended**			**Year ended**
		30-Jun-2026	**31-Mar-2026 (Restated)**	**30-Jun-2025**	**31-Mar-2026 (Restated)**
Paid up debt capital		11390	11390	643	11390
Net worth	52(4)(f)	17754	17576	8117	17576
Debenture redemption reserve	52(4)(e)	-	-	36	-
Debt equity ratio (in times)	52(4)(a)	0.78	0.81	0.27	0.81
Debt service coverage ratio (in times)	52(4)(b)	3.88	3.85	5.55	3.27
Interest service coverage ratio (in times)	52(4)(c)	4.40	4.77	17.21	10.09
Current ratio (in times)	52(4)(i)	1.29	1.22	1.71	1.22
Long term debt to working capital (in times)	52(4)(j)	5.55	7.29	0.60	7.29
Bad debts to Account receivables ratio (in times)	52(4)(k)	0.01	0.01	0.00	0.01
Current liability ratio (in times)	52(4)(l)	0.26	0.26	0.56	0.26
Total debts to total assets (in times)	52(4)(m)	0.33	0.34	0.17	0.34
Debtors turnover (in times) (Annualised)	52(4)(n)	4.67	4.74	4.52	4.06
Inventory turnover (in times) (Annualised)	52(4)(o)	7.52	7.26	6.63	6.00
Operating margin (in %)	52(4)(p)	37.2%	34.6%	37.2%	36.8%
Net profit margin (in %)	52(4)(q)	11.8%	9.0%	21.1%	17.8%
Security cover ratio (in times)	54(3)	1.44	1.47	9.41	1.47

Ratios have been computed as follows :-

(a) Debt equity ratio : Total debt / Net worth
  Total debt: Non-current borrowings + current borrowings
  Net worth: Equity share capital + Other equity

(b) Debt service coverage ratio : (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / (Interest on debt and lease + Principal repayments of long term debt including lease payment)

(c) Interest service coverage ratio: (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / Interest on debt and lease

(d) Current Ratio : Total current assets / Total current liabilities

(e) Long term debt to working capital : Non-current borrowings (incl. current maturities of long-term borrowings) / Net working capital
  Net Working capital : Total current assets - Current liabilities
  Current liabilities: Total current liabilities - current maturities of long-term borrowings

(f) Bad debts to Account receivables ratio : Allowances for expected credit loss / Gross trade receivables

(g) Current liability ratio : Total current liabilities / Total liabilities

(h) Total debts to total assets : Total borrowing / Total assets
  Total borrowing : Non-current borrowings + current borrowings

(i) Debtors turnover : Net sales / Average trade receivables

(j) Inventory turnover : Net sales / Average Inventories

(k) Operating margin % : Revenue from operations - (cost of goods sold + employee benefits + other expenses) + (other income - interest income - dividend income) / Revenue from operations

(l) Net profit margin % : Profit after tax / Revenue from operations

(m) Security cover ratio : Total assets available for secured debt securities (secured by either *pari-passu* or exclusive charge on assets including assets given on first *pari-passu* basis to term loan lenders) / Total borrowing through issue of secured Debt securities and other borrowings (secured by first *pari-passu* charge on aforementioned assets) including interest accrued.

TORRENT PHARMACEUTICALS LTD. AHMEDABAD

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Torrent Pharmaceuticals Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended

To the Board of Directors of Torrent Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021,as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Sadashiv Shetty
Partner
Membership No.: 048648
UDIN:26048648WWLMKT5706

Ahmedabad
30 July 2026

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Torrent Pharmaceuticals Limited	Parent
2	Zao Torrent Pharma	Wholly Owned Subsidiary
3	Torrent Do Brasil Ltda	Wholly Owned Subsidiary
4	Torrent Pharma Gmbh	Wholly Owned Subsidiary
5	Heumann Pharma Gmbh & Co. Generica KG	Wholly Owned Step down Subsidiary
6	Heunet Pharma Gmbh	Wholly Owned Step down Subsidiary
7	Torrent Pharma Inc.	Wholly Owned Subsidiary
8	Torrent Pharma Philippines Inc.	Wholly Owned Subsidiary
9	Laboratories Torrent, S.A. de C.V.	Wholly Owned Subsidiary
10	Torrent Australasia Pty Ltd	Wholly Owned Subsidiary
11	Torrent Pharma (Thailand) Co., Ltd.	Wholly Owned Subsidiary
12	Torrent Pharma (UK) Ltd.	Wholly Owned Subsidiary
13	Laboratories Torrent (Malaysia) SDN.BHD.	Wholly Owned Subsidiary
14	TPL (Malta) Limited	Wholly Owned Subsidiary
15	Torrent Pharma (Malta) Limited	Wholly Owned Step down Subsidiary
16	Curatio Inc., Philippines (voluntary dissolved with effect from 10 July 2026)	Wholly Owned Subsidiary
17	Torrent International Lanka (Pvt) Ltd (Formerly known as Curatio International Lanka (Pvt) Ltd), Sri Lanka	Wholly Owned Subsidiary
18	Farmacéutica Torrent Colombia SAS	Wholly Owned Subsidiary

19	Torrent Pharmaceuticals Chile SpA	Wholly Owned Subsidiary
20	OOO Unique Pharmaceutical Laboratories	Wholly Owned Subsidiary
21	Unique Pharmaceutical Laboratories FZE	Wholly Owned Subsidiary
22	Biotech Laboratories	Wholly Owned Step down Subsidiary
23	JBCPL Philippines Inc.	Wholly Owned Step down Subsidiary

TORRENT PHARMACEUTICALS LIMITED

Registered Office: "Avirat", Thaltej Shilaj Road, Ahmedabad – 380059, Gujarat, India, Ph.: + 91 79 26599000 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores)

Statement of Consolidated Financial Results for the Quarter ended June 30, 2026

	Particulars	**Quarter ended**			**Year ended**
		30-Jun-2026 Unaudited (Refer Note 6)	**31-Mar-2026 Audited (Refer Note 4 & 5)**	**30-Jun-2025 Unaudited (Refer Note 6)**	**31-Mar-2026 Audited (Refer Note 5)**
1	**Revenue from operations**				
	(a) Revenue from contracts with customers	4835	4128	3128	13753
	(b) Other operating income	86	69	50	227
	Total revenue from operations	**4921**	**4197**	**3178**	**13980**
2	Other income (Refer Note 8)	(12)	(17)	(37)	(94)
3	**Total income (1+2)**	**4909**	**4180**	**3141**	**13886**
4	**Expenses**				
	(a) Cost of materials consumed	609	566	396	1758
	(b) Purchases of stock-in-trade	531	477	338	1619
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	23	(28)	40	11
	(d) Employee benefits expense	893	788	605	2671
	(e) Finance costs	305	236	56	385
	(f) Depreciation and amortisation expense	593	508	201	1119
	(g) Other expenses	1201	1,038	767	3362
	Total expenses	**4155**	**3585**	**2403**	**10925**
5	**Profit before exceptional items and tax (3 - 4)**	**754**	**595**	**738**	**2961**
6	Exceptional items (Refer Note 7)	21	66	-	89
7	**Profit before tax (5 - 6)**	**733**	**529**	**738**	**2872**
8	**Tax expense**				
	(a) Current tax	254	166	201	844
	(b) Deferred tax	(87)	(1)	(11)	(110)
	Total tax expense	**167**	**165**	**190**	**734**
9	**Net profit for the period (7 - 8)**	**566**	**364**	**548**	**2138**
	Attributable to :				
	(a) Owners of the company	566	389	548	2163
	(b) Non-controlling interests	-	(25)	-	(25)
10	**Other comprehensive income**				
	(A) (i) Items that will not be reclassified subsequently to profit or loss*	(17)	21	(9)	0
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss*	4	(4)	2	0
	(B) (i) Items that will be reclassified subsequently to profit or loss	119	(127)	(2)	(228)
	(ii) Income tax relating to items that will be reclassified subsequently to profit or loss	(27)	24	7	48
	Total other comprehensive income	**79**	**(86)**	**(2)**	**(180)**
	Attributable to :				
	(a) Owners of the company	79	(87)	(2)	(181)
	(b) Non-controlling interests	-	1	-	1
11	**Total comprehensive Income (9 + 10)**	**645**	**278**	**546**	**1958**
	Attributable to :				
	(a) Owners of the company	645	302	546	1982
	(b) Non-controlling interests	-	(24)	-	(24)
12	Paid-up equity share capital (Face value of Rs. 5 each)	169.23	169.23	169.23	169.23
13	Other equity excluding revaluation reserves				8220
14	**Earnings per share (Face value of Rs. 5 each) (not annualised) :**				
	Basic (in Rs.)	14.87	11.51	16.19	63.92
	Diluted (in Rs.)	14.87	11.51	16.19	63.92

See accompanying notes to the consolidated financial results

*Represents value less than Rs. 0.50 crore.

Notes:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on July 30, 2026. The statutory auditors have carried out limited review of the above said results. There is no qualification in the auditor's report on this statement of financial results.

2. The consolidated financial results include the financial results of Parent Company and its twenty-two subsidiaries.

3. The Group operates in a single segment i.e. Generic Formulation Business.

4. Figures for the quarter ended March 31, 2026 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2025, which were subjected to limited review.

5. Consequent to the acquisition of the controlling stake of 48.80% in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma), the Parent Company obtained control over JB Pharma in accordance with Ind AS 110 – Consolidated Financial Statements with effect from January 21, 2026. The results for the year and quarter ended March 31, 2026, includes the financial results of JB Pharma and its subsidiaries w.e.f. January 21, 2026.

6. The Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) with the Parent Company was approved by the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, on July 6, 2026. Upon filing the Scheme with Registrar of Companies (ROC), the Scheme became effective on July 8, 2026, with an appointed date of January 21, 2026. Consequently, JB Pharma has been amalgamated with the Parent Company and dissolved without being wound up.

   On July 20, 2026, the Parent Company allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JB Pharma as on the record date, July 17, 2026, in the share exchange ratio of 51 equity shares having face value of Rs. 5 each of the Parent Company for every 100 equity shares having face value of Rs. 1 each of JB Pharma.

   Upon Scheme becoming effective, the non-controlling interest relating to JB Pharma has been derecognised in the consolidated financial results. The amalgamation has no material impact on the consolidated financial results.

   The financial results do not include the effect of the stamp duty payable in respect of the Scheme of Amalgamation, pending adjudication by the appropriate authority.

7. Exceptional items

   (i) Includes Rs. 2 crores for the quarter ended June 30, 2026, Rs. 47 crores and Rs. 70 crores for quarter and year ended March 31, 2026 respectively, pertaining to regulatory and statutory fees, along with other related costs associated with JB Pharma's acquisition and merger as mentioned in Note 5 and 6 above.

   (ii) Includes inventory write-off of Rs. 19 crores for the quarter ended June 30, 2026 consequent to fire incident at one of the erstwhile JB Pharma warehouses. No effect has been given to the related insurance claim, which is under assessment.

   (iii) Includes severance compensation of Rs. 19 crores for the quarter and year ended March 31, 2026, incurred on account of restructuring of JB Pharma's distribution network.

TORRENT PHARMACEUTICALS LTD.
AHMEDABAD

8 Other income mainly includes interest income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets.

9 Refer Annexure I for disclosure required pursuant to Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

For TORRENT PHARMACEUTICALS LIMITED

AMAN MEHTA
Managing Director
DIN : 08174906

Place : Ahmedabad, Gujarat
Date : July 30, 2026

ANNEXURE I : **(Rs. in crores except as stated otherwise)**

Additional Disclosure as per regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015					
Particulars	**Regulation No.**	**Quarter ended**			**Year ended**
		30-Jun-2026	**31-Mar-2026**	**30-Jun-2025**	**31-Mar-2026**
Paid up debt capital		11390	11390	643	11390
Net worth	52(4)(f)	17848	8389	8137	8389
Debenture redemption reserve	52(4)(e)	-	-	36	-
Debt equity ratio (in times)	52(4)(a)	0.82	1.76	0.33	1.76
Debt service coverage ratio (in times)	52(4)(b)	3.98	4.09	5.10	3.26
Interest service coverage ratio (in times)	52(4)(c)	4.60	4.97	14.20	9.41
Current ratio (in times)	52(4)(i)	1.20	1.13	1.35	1.13
Long term debt to working capital (in times)	52(4)(j)	6.37	9.26	0.83	9.26
Bad debts to Account receivables ratio (in times)	52(4)(k)	0.02	0.02	0.01	0.02
Current liability ratio (in times)	52(4)(l)	0.31	0.31	0.62	0.31
Total debts to total assets (in times)	52(4)(m)	0.33	0.33	0.18	0.33
Debtors turnover (in times) (Annualised)	52(4)(n)	6.09	6.60	6.73	5.62
Inventory turnover (in times) (Annualised)	52(4)(o)	6.14	5.87	4.97	4.84
Operating margin (in %)	52(4)(p)	33.2%	31.5%	31.1%	31.7%
Net profit margin (in %)	52(4)(q)	11.5%	8.7%	17.2%	15.3%

Ratios have been computed as follows :-

(a) Debt equity ratio : Total debt / Net worth
  Total debt: Non-current borrowings + current borrowings
  Net worth: Equity share capital + Other equity

(b) Debt service coverage ratio : (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / (Interest on debt and lease + Principal repayments of long term debt including lease payment)

(c) Interest service coverage ratio: (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / Interest on debt and lease

(d) Current Ratio : Total current assets / Total current liabilities

(e) Long term debt to working capital : Non-current borrowings (including current maturities of long-term borrowings) / Net working capital
  Net Working capital : Total current assets - Current liabilities
  Current liabilities: Total current liabilities - current maturities of long-term borrowings

(f) Bad debts to Account receivables ratio : Allowances for expected credit loss / Gross trade receivables

(g) Current liability ratio : Total current liabilities / Total liabilities

(h) Total debts to total assets : Total borrowing / Total assets
  Total borrowing : Non-current borrowings + current borrowings

(i) Debtors turnover : Net sales / Average trade receivables

(j) Inventory turnover : Net sales / Average Inventories

(k) Operating margin % : Revenue from operations - (cost of goods sold + employee benefits + other expenses) + (other income - interest income - dividend income) / Revenue from operations

(l) Net profit margin % : Profit after tax / Revenue from operations

TORRENT PHARMACEUTICALS LTD. AHMEDABAD

Annexure B

MEDIA RELEASE

Torrent Pharma announces Q1 FY27 results

India business delivers record high organic growth; JB Business revenues up 10%

Ahmedabad, 30th July 2026: Torrent Pharmaceuticals Limited ("Company") today announced its financial results for the first quarter of FY27.

Key Highlights for Q1 FY27:

- Revenue at Rs. 4,921 crores, up by 55% YoY
- Op. EBITDA* at Rs.1,664 crores, up by 61% YoY
- Op. EBITDA* margin at 33.8%; Gross Margin at 76.4%
- Net Profit after tax at Rs. 566 crores

**Before exceptional items*

Consolidated Financial Summary:

Results	Q1 FY27		Q1 FY26		YoY %
	Rs cr	%	Rs cr	%	
Revenues	4,921		3,178		55%
Gross profit	3,758	76.4%	2,404	75.6%	56%
Op. EBITDA*	1,664	33.8%	1,032	32.5%	61%
Exceptional items	21	0.4%	-	-	-
PAT	566	11.5%	548	17.2%	3%
R&D spend	172	4%	157	5%	10%

Base Business

Base business revenues at Rs. 3,720 crores were up 17%

Op. EBITDA* at Rs. 1,240 crores grew by 20%, with margins of 33.3%

India:

- India revenues at Rs. 2,157 crores were up 19% vs IPM growth of 12%, as per the AIOCD PharmaTrac dataset
- Torrent is now ranked 1st in the IPM cardiac market, and continues strong outperformance in the segment
- Following a strong start, Gx Semaglutide recorded Q1 FY27 market share of 36% (oral and injectable combined), as per AIOCD PharmaTrac Data

Brazil:

- Brazil revenues at Rs. 277 crores were up 27%. Constant currency revenues at R$ 147 million were up by 3%.
- As per IQVIA, Torrent grew 21% vs market growth of 5%, aided by the performance of top brands and recent launches. Torrent has 58 products under ANVISA review
- During the quarter, the Company undertook a one-time channel inventory reduction in response to channel requests for extended credit periods amid rising interest costs. Secondary sales continue to reflect underlying demand momentum as reflected in IQVIA data.

United States:

- US revenues at Rs. 418 crores were up 36%. Constant currency revenues at US$ 44 million were up by 23%
- Performance is driven by new launches achieving targeted market share and certain one-time opportunities.

Germany:

- Germany revenues at Rs. 318 crores were up 3%. Constant currency revenues at EUR 29 million were down by 9%
- Growth continued to be impacted by supply disruption at a third-party supplier and lower tender offtake during the quarter

JB Business

Results	Q1 FY27		Q1 FY26		YoY %
	Rs cr	%	Rs cr	%	
Revenues	1,201		1,094		10%
Gross profit	859	71.5%	747	68.3%	15%
Op. EBITDA*	424	35.3%	315	28.8%	34%
Exceptional items	19	1.6%	-	-	-

** Before exceptional items and one offs*

Key Performance Metrics:

- **India Rx business** (ex of trade generics + contrast media) at Rs. 657 cr grew by 13%
- **International business** (US + Emerging Markets + CDMO) revenues at Rs. 468 crores were up 12%
    - **CDMO** business revenues at Rs. 145 crores were up 27%

Consolidated Revenue Summary

Region	Q1 FY27 (Rs. crore)			Q1 Growth (%)	
	Base Business	JB Business	Total	Base Business	Reported
India	2,157	733	2,890	19%	60%
International	1,451	468	1,919	19%	57%
Others	112	-	112	-24%	-24%
Total	**3,720**	**1,201**	**4,921**	**17%**	**55%**

About Torrent Pharmaceuticals:

Torrent Pharma is the flagship Company of the Torrent Group, with group revenues of approximately Rs 50,000 crores. It is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Derma.

It is a specialty-focused company with ~75% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent Pharma has 16 manufacturing facilities, of which 8 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 900+ scientists.